5–10 mg ×3 in the studies.
Possible improvement in vascular dementia; older studies of variable quality.
See the study (review (Cochrane)) →⏱ 3 min read
Vinpocetine is a semisynthetic alkaloid derived from vincamine, a compound present in the leaves of the lesser periwinkle (Vinca minor), a European perennial plant with documented traditional use for cerebral circulatory problems; it was developed in Hungary in the 1970s and has been marketed since then as a drug (Cavinton) in many European and Asian countries for cognitive impairment of cerebrovascular origin, vascular dementia, and stroke sequelae, while in the United States and other markets it is sold as a nootropic supplement, a heterogeneous regulatory classification that reflects the intermediate nature of this compound between drug and supplement.
The mechanism of action is multiple and combines several relevant pharmacological effects: selective cerebral vasodilation with improved regional blood flow in hypoperfused areas, inhibition of phosphodiesterase-1 (with an increase in cerebral cGMP), modulation of neuronal sodium and calcium channels with a neuroprotective effect, and antioxidant and anti-inflammatory properties; this profile gives it activity on brain function with a relatively solid mechanistic basis but with heterogeneous clinical data regarding effect size and replicability outside the countries where it has been studied as a drug.
The indication with the most solid clinical support is cognitive impairment of cerebrovascular origin and mild to moderate vascular dementia: several European and Asian trials have documented significant improvements in cognitive scales (MMSE, ADAS-cog) and functional scales with doses of 30-60 milligrams per day for 12-24 weeks, with magnitudes comparable to those of some drugs specific for dementia.
A Cochrane meta-analysis on vinpocetine in dementia published in 2003 concluded that although there are data suggesting benefit, the methodological quality of the available studies is heterogeneous and does not allow firm clinical recommendations; later reviews have given a more positive nuance to the assessment, particularly for vascular dementia, where the data are more consistent than for Alzheimer's disease.
In recovery from ischemic stroke, several studies have documented improvements in neurological and cognitive function with supplementation for months after the acute event, an indication recognized in some European neurological guidelines and frequently used in integrative neurological rehabilitation.
In tinnitus and vertigo attributed to mild vertebrobasilar insufficiency, several small studies have shown symptomatic improvements with supplementation over weeks to months, an indication consistent with improved cerebral circulation and with modest clinical support.
In healthy adults without cognitive deficit, the evidence is limited and does not support significant improvements with supplementation; the data suggest that vinpocetine works best when there is a substrate of cerebral hypoperfusion or microvascular dysfunction, not as a general cognitive enhancer in people with normal perfusion, an important distinction for understanding its real role.
The doses studied range from 15 to 60 milligrams per day, divided into 2-3 doses with meals to improve absorption (vinpocetine has better oral bioavailability with a fatty meal); typical commercial products contain 10-15 mg per capsule; the cognitive effect appears gradually and requires at least 8-12 weeks for clinical assessment; products sold as regulated drugs in European countries have better standardization than North American nutritional supplements.
Generally well tolerated at the doses studied; the most frequent adverse effects are headache, dizziness, digestive discomfort, mild hypotension, and, occasionally, transient hypoglycemia; people taking anticoagulants should be cautious because of a documented mild antiplatelet effect; those taking antihypertensives may experience potentiation of the hypotensive effect; people with arrhythmias should be cautious because of modulation of cardiac calcium channels; people who are going to undergo surgery should stop vinpocetine at least 1-2 weeks beforehand because of the antiplatelet effect; it is contraindicated in pregnancy because of preclinical data showing reduced fetal weight and increased risk of miscarriage, a documented risk serious enough that the US FDA has issued specific warnings about the use of vinpocetine as a supplement in women of childbearing age; in breastfeeding, data are limited and use is discouraged; supplement products without pharmaceutical regulation have heterogeneous quality and standardization, and it is advisable to choose products with good quality control.
Information, not medical advice. Scientific evidence reflects the quality of the studies.